BLUE - Stockholder Alert: Robbins LLP Reminds BLUE Investors of Upcoming May 28 2024 Lead Plaintiff Deadline in the Bluebird Bio Inc. Class Action | Benzinga
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. (NASDAQ:BLUE) common stock between April 24, 2023 and December 8, 2023. Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
According to the complaint, on April 24, 2023, defendants announced submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events (VOEs). The BLA also included a request for priority review, which, if granted, would shorten the FDA's review of the application to six months from the time of filing, versus a standard review timeline of 10 months.
On December ...